Product-focused roadmap shows how MSC secretomes can become scalable, standardized, GMP-ready biotherapeutics.
Glioblastomas (GBMs) are highly aggressive cancerous tumors of the brain and spinal cord. Brain cancers like GBM are challenging to treat because many cancer therapeutics cannot pass through the blood ...
Approximately 15-to-30 percent of patients with metastatic breast cancer have brain metastasis (BM), with basal-like breast cancer (BLBC) metastasizing to the brain most frequently. The prognosis for ...
Glioblastomas (GBMs) are highly aggressive cancerous tumors of the brain and spinal cord. Brain cancers like GBM are challenging to treat because many cancer therapeutics cannot pass through the blood ...
Glioblastomas (GBMs) are highly aggressive tumors of the brain and spinal cord that are challenging to treat because many cancer therapeutics cannot pass through the blood-brain barrier. Scientists ...
LOS ANGELES & MONROVIA, Calif.--(BUSINESS WIRE)--CytoImmune Therapeutics, a clinical-stage immuno-oncology company that is developing a novel class of engineered natural killer (NK) cell-based cancer ...
Investigators have devised a novel therapeutic method for treating glioblastomas post-surgery by using stem cells taken from healthy donors engineered to attack GBM-specific tumor cells. This strategy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results